Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

30.65 +1.53 (+5.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Preview: Vaxcyte's Earnings
Via Benzinga
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Expert Ratings for Vaxcyte
Via Benzinga
Why Shares of Vaxcyte Rose 110.7% This Week
The company released early data for a promising pneumonia vaccine. 
Via The Motley Fool
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
Via Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Vaxcyte to Present at Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet. 
Via MarketBeat
Exposures COVID-19
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Vaxcyte Announces Pricing of $600 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. 
Via Benzinga
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge
U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday. 
Via Benzinga
Vaxcyte Shares Surge As Its Pneumococcal Vaccine On Par With Pfizer's Shot In Study
Via Benzinga
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida (TCDA) stock is falling on Monday following the release of poor results from a Phase 3 chronic kidney disease clinical trial. 
Via InvestorPlace
How Is The Market Feeling About Vaxcyte?
Vaxcyte's (NASDAQ:PCVX) short percent of float has risen 22.85% since its last report. The company recently reported that it has 2.48 million shares sold short, which is 5.43% of all regular shares... 
Via Benzinga
Why Is Vaxcyte (PCVX) Stock Up 70% Today?
Vaxcyte (PCVX) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. 
Via InvestorPlace
US Stocks Mixed; Dow Jumps 200 Points
U.S. stocks traded mixed this morning, with the Dow Jones surging around 200 points on Monday. 
Via Benzinga
Vaxcyte Shares Are Soaring: Here's Why
Vaxcyte Inc (NASDAQ: PCVX) shares are trading higher Monday after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS